Endocrine pancreatic tumors in von hippel-lindau disease: Clinical, histological, and genetic features

Pancreas

Volumn 37, Issue 1, 2008, Pages 85-93

  Corcos, Olivier ^a   Couvelard, Anne ^a   Giraud, Sophie ^b   Vullierme, Marie Pierre ^a   Dermot O'Toole, ^a   Rebours, Vinciane ^a   Stievenart, Jean Louis ^a   Penfornis, Alfred ^c   Niccoli Sire, Patricia ^d   Baudin, Eric ^e   Sauvanet, Alain ^a   Levy, Philippe ^a   Ruszniewski, Philippe ^a   Richard, Stéphane ^f   Hammel, Pascal ^a  

^a BEAUJON HOSPITAL   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^d TIMONE HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Endocrine carcinoma; Endocrine tumors; Pancreas; Somatostatin receptor scintigraphy; Survival; Von Hippel Lindau disease

Indexed keywords

KI 67 ANTIGEN; SOMATOSTATIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN; SOMATOSTATIN RECEPTOR; VHL PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC CORRELATION; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MUTATIONAL ANALYSIS; PANCREAS ISLET CELL TUMOR; PEDIGREE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; SCINTISCANNING; TUMOR BIOPSY; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR VOLUME; VON HIPPEL LINDAU DISEASE; CHEMISTRY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FRANCE; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PANCREAS ISLET; PANCREAS TUMOR; PATHOLOGY; PHENOTYPE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; FEMALE; FRANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; GERM-LINE MUTATION; HUMANS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHENOTYPE; PROGNOSIS; RADIONUCLIDE IMAGING; RECEPTORS, SOMATOSTATIN; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 49649106968     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31815f394a     Document Type: Article

References (44)

1. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317-1320.
2. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059-2067.
3. Lee S, Chen DY, Humphrey JS, et al. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A. 1996;93:1770-1775.
4. Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A. 1997;94:2156-2161.
5. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673-682.
6. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275.
7. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485-490.
8. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991-5004.
9. Zbar B, Kishida T, Chen F, et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 1996;8:348-357.
10. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12:417-423.
11. Beroud C, Joly D, Gallou C, et al. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res. 1998;26: 256-258.
12. Binkovitz LA, Johnson CD, Stephens DH. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol. 1990;155: 501-505.
13. Neumann HP, Dinkel E, Brambs H, et al. Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology. 1991;101:465-471.
14. Hough DM, Stephens DH, Johnson CD, et al. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol. 1994;162:1091-1094.
15. Hammel P, Beigelman C, Chauveau D, et al. Variety of pancreatic lesions observed in von Hippel-Lindau disease. A propos of 8 cases. Gastroenterol Clin Biol. 1995;19:1011-1017.
16. Maki M, Kaneko Y, Ohta Y, et al. Somatostatinoma of the pancreas associated with von Hippel-Lindau disease. Intern Med. 1995;34:661-665.
17. Libutti SK, Choyke PL, Bartlett DL, et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery. 1998;124:1153-1159.
18. Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 2000;119:1087-1095.
19. Marcos HB, Libutti SK, Alexander HR, et al. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology. 2002; 225:751-758.
20. Lubensky IA, Pack S, Ault D, et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol. 1998;153:223-231.
21. Cadiot G, Mignon M. Somatostatin-receptor scintigraphy in endocrine tumors. Gastroenterology. 1994;106:1723-1724.
22. Jamar F, Fiasse R, Leners N, et al. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med. 1995;36:542-549.
23. Cadiot G, Lebtahi R, Sarda L, et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. Gastroenterology. 1996;111:845-854.
24. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996;125:26-34.
25. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32:84-91.
26. Lebtahi R, Cadiot G, Mignon M, et al. Somatostatin receptor scintigraphy: a first-line imaging modality for gastroenteropancreatic neuroendocrine tumors. Gastroenterology. 1998;115:1025-1027.
27. Richard S, Graff J, Lindau J, et al. Von Hippel-Lindau disease. Lancet. 2004;363:1231-1234.
28. Rosch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992;326:1721-1726.
29. Ruszniewski P, Amouyal P, Amouyal G, et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery. 1995;117:629-635.
30. Solcia E, Klöppel G, Sobin LH. Histological Typing of Endocrine Tumours. New York: Springer; 2000.
31. Rindi G, Capella C, Bordi C, et al. Guidelines and minimal diagnostic criteria for the histological diagnosis of endocrine tumors of the gastroenteropancreatic type. Pathologica. 2002;94:142-147.
32. Gentil Perret A, Mosnier JF, Buono JP, et al. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am J Clin Pathol. 1998;109:286-293.
33. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol. 1996;27:1124-1134.
34. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323-333.
35. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.
36. Choyke PL, Glenn GM, Walther MM, et al. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology. 1995;194: 629-642.
37. Taouli B, Ghouadni M, Correas JM, et al. Spectrum of abdominal imaging findings in von Hippel-Lindau disease. AJR Am J Roentgenol. 2003;181:1049-1054.
38. Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95: 2271-2277.
39. Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994;3: 1303-1308.
40. Libutti SK, Choyke PL, Alexander HR, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000;128:1022-1027;discussion 1027-1028.
41. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422-427.
42. Hasebe T, Sasaki S, Imoto S, et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol. 2002;15:502-516.
43. Couvelard A, O'Toole D, Leek R, et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology. 2005;46:668-676.
44. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440: 461-475.